Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia

Yinglin Huang,1,2 Huan Ma,1 Yuan Wang,2 Miao Peng,2 Gang Zhu1 1Department of Psychiatry, The First Affiliated Hospital of China Medical University, 2Department of Psychiatry, Shengjing Hospital of China Medical University, Shenyang, China Abstract: Topiramate has been used increasingly in the mana...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huang Y, Ma H, Wang Y, Peng M, Zhu G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Topiramate prolactin schizophrenia antipsychotics dopamine alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/7fce3565f68f4be1b8643d1dd3232f3d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7fce3565f68f4be1b8643d1dd3232f3d
record_format	dspace
spelling	oai:doaj.org-article:7fce3565f68f4be1b8643d1dd3232f3d2021-12-02T03:59:52ZTopiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia1178-2021https://doaj.org/article/7fce3565f68f4be1b8643d1dd3232f3d2017-05-01T00:00:00Zhttps://www.dovepress.com/topiramate-add-on-treatment-associated-with-normalization-of-prolactin-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Yinglin Huang,1,2 Huan Ma,1 Yuan Wang,2 Miao Peng,2 Gang Zhu1 1Department of Psychiatry, The First Affiliated Hospital of China Medical University, 2Department of Psychiatry, Shengjing Hospital of China Medical University, Shenyang, China Abstract: Topiramate has been used increasingly in the management of psychiatric conditions. Clinical trials demonstrated that topiramate augmentation was effective in controlling negative symptoms in schizophrenia. This case report presents a case of a 38-year-old man with schizophrenia who achieved full negative symptom remission upon the adjunctive use of topiramate. However, the remarkable finding of this case is the concomitant decrease in the level of prolactin when topiramate (50 mg/day) was started and the rebound after discontinuation of topiramate. Previous studies stated that topiramate could prevent antipsychotic-induced weight gain and adverse metabolic effects. To the authors’ knowledge, no study has reported that topiramate augmentation could be a treatment strategy for antipsychotic-induced hyperprolactinemia. This finding could be verified by well-designed clinical trials. Keywords: topiramate, prolactin, schizophrenia, antipsychotics, dopamine, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)Huang YMa HWang YPeng MZhu GDove Medical PressarticleTopiramateprolactinschizophreniaantipsychoticsdopaminealpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 1395-1397 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Topiramate prolactin schizophrenia antipsychotics dopamine alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Topiramate prolactin schizophrenia antipsychotics dopamine alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Huang Y Ma H Wang Y Peng M Zhu G Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia
description	Yinglin Huang,1,2 Huan Ma,1 Yuan Wang,2 Miao Peng,2 Gang Zhu1 1Department of Psychiatry, The First Affiliated Hospital of China Medical University, 2Department of Psychiatry, Shengjing Hospital of China Medical University, Shenyang, China Abstract: Topiramate has been used increasingly in the management of psychiatric conditions. Clinical trials demonstrated that topiramate augmentation was effective in controlling negative symptoms in schizophrenia. This case report presents a case of a 38-year-old man with schizophrenia who achieved full negative symptom remission upon the adjunctive use of topiramate. However, the remarkable finding of this case is the concomitant decrease in the level of prolactin when topiramate (50 mg/day) was started and the rebound after discontinuation of topiramate. Previous studies stated that topiramate could prevent antipsychotic-induced weight gain and adverse metabolic effects. To the authors’ knowledge, no study has reported that topiramate augmentation could be a treatment strategy for antipsychotic-induced hyperprolactinemia. This finding could be verified by well-designed clinical trials. Keywords: topiramate, prolactin, schizophrenia, antipsychotics, dopamine, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)
format	article
author	Huang Y Ma H Wang Y Peng M Zhu G
author_facet	Huang Y Ma H Wang Y Peng M Zhu G
author_sort	Huang Y
title	Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia
title_short	Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia
title_full	Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia
title_fullStr	Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia
title_full_unstemmed	Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia
title_sort	topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/7fce3565f68f4be1b8643d1dd3232f3d
work_keys_str_mv	AT huangy topiramateaddontreatmentassociatedwithnormalizationofprolactinlevelsinapatientwithschizophrenia AT mah topiramateaddontreatmentassociatedwithnormalizationofprolactinlevelsinapatientwithschizophrenia AT wangy topiramateaddontreatmentassociatedwithnormalizationofprolactinlevelsinapatientwithschizophrenia AT pengm topiramateaddontreatmentassociatedwithnormalizationofprolactinlevelsinapatientwithschizophrenia AT zhug topiramateaddontreatmentassociatedwithnormalizationofprolactinlevelsinapatientwithschizophrenia
_version_	1718401500218130432

Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia

Ejemplares similares